Clinically studied liver brand: $3.5M TTM, $1.29M/yr subs, $139 AOV, 81% margin, $431K adj. EBITDA

This is a high-margin, subscription-first daily liver and metabolic health brand for adults who drink, selling a clinically studied supplement through Shopify and Amazon. The product is rated 4.8 stars across 773+ verified reviews, customers stay on multi-month subscriptions, and operations are fully outsourced. In 20 months the company generated $5.5M in gross sales ($4.8M net revenue through September), including $3.54M in the last 12 months, with 25,000+ customers across Shopify and Amazon. Adjusted EBITDA before management compensation was $431K for the 12 months to June 2026: $255.9K of EBITDA plus $174.6K of one-off projects, ended retainers and owner items, verified line by line in a general-ledger review. The platform's $196.7K net profit covers the year to September, a different period. ✅ $107K a month in subscription MRR across 2,659 active subscriptions (Loop $83.9K, Amazon Subscribe & Save $23.6K average); more than half of September revenue came from subscription renewals, and 6-month plans collect $239 upfront ✅ 49% of 6-month and 57% of 3-month subscribers renew for another term; subscribers are worth $339 each to date and still rising, and 2026 cohorts retain like 2025 ✅ Completed 12-week pre/post study of the finished formula, run by an independent research company: 92% woke refreshed more often, 94% improved on five or more of nine outcomes, 75% had a decrease in at least one liver enzyme ✅ Exclusive on-demand inventory agreement: avoids funding large production runs, with about $31K of stock on hand ✅ Exclusive rights to a patented ingredient, 1,000+ clinician recommendations, a first direct clinic order (October 2026) and an at-home liver blood test kit ✅ Built by founders with prior exits and advised by operators behind notable consumer-health and beverage-brand exits ✅ Growth upside: the new study claims in ads, retail and practitioner channels, Amazon, 11,500+ one-time buyers to convert, new SKUs and international expansion

Asking Price

$2.3M

Multiples

Asking Price Reasoning

0.64x TTM revenue and 5.2x adjusted EBITDA before management compensation ($431K, 12 months to June 2026). The platform's 11.4x uses net profit to September, which carries a funded clinical study, financing costs and agencies since discontinued. After Meta's Andromeda update raised acquisition costs across DTC health in 2026, the founders cut unprofitable ad spend, protected the subscription base (more than half of September revenue; $107K a month MRR), completed the 12-week study and secured exclusive ingredient rights. A buyer gets 81% gross margins, an exclusive on-demand agreement that avoids funding large production runs, prepaid plans that collect cash upfront, and study claims not yet used in ads. A strategic adds retail, Amazon or practitioner reach; an operator restarts acquisition on an established base. Open to cash plus an earnout or seller note.

$3.5M last 12 months gross revenue

$196.7k last 12 months net profit

$160k last month gross revenue

$-414 last month net profit

United States

+180% Annual Growth Rate

5,000+ Customers

8 SKUs

30983 Total Value of Inventory

Date Founded

March 2025

Team Size

Small (2-20)

Business Model

Business-to-consumer (B2C)
Subscription
Ecommerce
Direct-to-consumers (DTC)

Prepaid 1, 3, 6 and 9-month plans on Loop subscriptions (average charge $184; 6-month plan $239, collected upfront), plus Amazon Subscribe & Save (722 active; Amazon puts subscriber 24-month value at $215 vs $54 for one-time buyers). An exclusive on-demand inventory agreement means the manufacturer produces as needed, so large production runs are not funded upfront; fulfilment is outsourced to a US 3PL, so a small team runs it. The annual growth figure compares the last 12 months with a partial launch year.

Tech Stack

Shopify

Shopify store with Loop Subscriptions, Klaviyo email and SMS, Judge.me reviews, Amazon Seller Central, QuickBooks and Triple Whale attribution.

Growth Opportunities

Increase digital marketing
Focus on SEO
Improve conversion rates
Expand to new markets
Increase content marketing

Put the completed study's results (final October 2026) into ads and landing pages. Take the product into retail and practitioner channels, which the study and 1,000+ recommending clinicians suit; the first direct clinic order came in October 2026. Use the at-home liver blood test kit as a front-end offer and retention tool. Add study claims to Amazon. Launch the exclusive ingredient as an upgrade or new SKU. Convert 11,500+ one-time buyers to subscription. Expand to Canada, the UK, Australia and Europe.

Competitors

Cheers Health
ZBiotics
Dose Daily
Morning Recovery

Key Assets

Marketing materials
Copyright
Domain
Social media accounts
Inventory
Trademarks
Intellectual property
Brand
Customers
Website
Other
Clinical Trial
Exclusive ingredient rights

Selling Reasoning

Financial gain
Starting a new venture

The founders built the product, the proof and the customer base. The next stage, retail and scaled acquisition, needs an owner with distribution or capital. Founders will support the transition.

Financing

Angel investment

Sign up to request access to this startup

Clinically studied liver brand: $3.5M TTM, $1.29M/yr subs, $139 AOV, 81% margin, $431K adj. EBITDA

Seller details

Startup details

Data room

Get more with Platinum